We are live on ! Find out more
ALLO icon

Allogene Therapeutics
ALLO

192 hedge funds and large institutions have $1.15B invested in Allogene Therapeutics in 2022 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 65 increasing their positions, 49 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

267% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 12

33% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 49

19% more funds holding

Funds holding: 161 → 192 (+31)

19% more call options, than puts

Call options by funds: $1.99M | Put options by funds: $1.67M

3.71% more ownership

Funds ownership: 70.2% → 73.91% (+3.7%)

0% less capital invested

Capital invested by funds: $1.15B → $1.15B (-$1.8M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

Holders
192
Holders Change
+31
Holders Change %
+19.25%
% of All Funds
3.31%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
44
Increased
65
Reduced
49
Closed
12
Calls
$1.99M
Puts
$1.67M
Net Calls
+$318K
Net Calls Change
-$674K

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$13.9M
2
Capital International Investors
Capital International Investors
California
+$13.4M
3
Citadel Advisors
Citadel Advisors
Florida
+$11M
4
Two Sigma Investments
Two Sigma Investments
New York
+$9.16M
5
Millennium Management
Millennium Management
New York
+$8.42M

Top Sellers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
-$18.1M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$16.9M
3
AllianceBernstein
AllianceBernstein
Tennessee
-$7.38M
4
JP Morgan Chase
JP Morgan Chase
New York
-$7.3M
5
Morgan Stanley
Morgan Stanley
New York
-$7.08M
Name Holding Trade Value Shares
Change 		Change in
Stake
GC
51
Gratus Capital
Georgia
$2.57M +$328K +24,173 +11%
EVM
52
Eaton Vance Management
Massachusetts
$2.56M – – –
ECM
53
ExodusPoint Capital Management
New York
$2.41M +$2.62M +192,738 +632%
Two Sigma Advisers
54
Two Sigma Advisers
New York
$2.4M +$1.22M +90,000 +68%
Swiss National Bank
55
Swiss National Bank
Switzerland
$2.21M +$34K +2,500 +1%
Susquehanna International Group
56
Susquehanna International Group
Pennsylvania
$2.19M +$561K +41,307 +26%
TC
57
TwinBeech Capital
New York
$2.11M +$2.66M +195,435 New
UBS Group
58
UBS Group
Switzerland
$1.96M +$601K +44,207 +32%
Mitsubishi UFJ Asset Management
59
Mitsubishi UFJ Asset Management
Japan
$1.86M +$6.54K +481 +0.3%
Thrivent Financial for Lutherans
60
Thrivent Financial for Lutherans
Minnesota
$1.8M +$1.67M +123,176 +284%
Jane Street
61
Jane Street
New York
$1.78M +$1.1M +80,706 +96%
TD Asset Management
62
TD Asset Management
Ontario, Canada
$1.7M +$499K +36,706 +29%
Macquarie Group
63
Macquarie Group
Australia
$1.6M -$14.9K -1,097 -0.7%
Manulife (Manufacturers Life Insurance)
64
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.55M -$8.79K -647 -0.4%
RhumbLine Advisers
65
RhumbLine Advisers
Massachusetts
$1.39M +$138K +10,174 +9%
JF
66
Jump Financial
Illinois
$1.36M +$1.72M +126,366 New
VOYA Investment Management
67
VOYA Investment Management
Georgia
$1.34M +$1.28M +94,369 +314%
MCM
68
Moore Capital Management
New York
$1.3M +$1.63M +119,972 New
Qube Research & Technologies (QRT)
69
Qube Research & Technologies (QRT)
United Kingdom
$1.26M +$1.59M +117,057 New
Vontobel Holding
70
Vontobel Holding
Switzerland
$1.23M +$55.3K +4,067 +4%
PP
71
PDT Partners
New York
$1.22M -$1.16M -85,018 -43%
HF
72
HRT Financial
New York
$1.19M +$1.5M +110,259 New
California State Teachers Retirement System (CalSTRS)
73
California State Teachers Retirement System (CalSTRS)
California
$1.14M -$18.9K -1,394 -1%
Swedbank
74
Swedbank
Sweden
$1.14M +$1.43M +105,500 New
GCM
75
Graham Capital Management
Connecticut
$1.12M -$1.78M -130,975 -56%
1 2
3
4 5

ALLO Hedge Fund Activity: Q3 2022 in Review

192 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q3 2022, worth a combined $1.15B — down 0.16% from $1.15B a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new ALLO positions and 12 closed out — a net gain of 32 holders — while 65 added to existing stakes and 49 trimmed.

The largest buyer was State Street, adding an estimated $13.9M. The largest seller was Woodline Partners, cutting an estimated $18.1M.

  • 192 institutional investors held Allogene Therapeutics (ALLO) as of Q3 2022, up from 161 in Q2 2022.
  • Funds reported $1.15B of Allogene Therapeutics stock for Q3 2022, down 0.16% quarter-over-quarter.
  • 44 funds opened new Allogene Therapeutics positions in Q3 2022 and 12 closed out, a net change of +32 holders.
  • The largest Allogene Therapeutics buyer in Q3 2022 was State Street, an estimated $13.9M added.
  • The largest Allogene Therapeutics seller in Q3 2022 was Woodline Partners, an estimated $18.1M sold.

Based on aggregated 13F filings for Q3 2022.